Indication
Gonorrhea
14 clinical trials
25 products
1 drug
Clinical trial
A Phase III, Randomized, Multicenter, Open-Label Study in Adolescent and Adult Participants Comparing the Efficacy and Safety of Gepotidacin to Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria GonorrhoeaeStatus: Completed, Estimated PCD: 2023-10-10
Product
GepotidacinProduct
CeftriaxoneProduct
AzithromycinProduct
EVO100Clinical trial
Phase 3 Double-blind Placebo-controlled Efficacy Trial of EVO100 Vaginal Gel for the Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae InfectionStatus: Completed, Estimated PCD: 2022-07-28
Product
PlaceboClinical trial
Effect of Trumenba on Gonococcal Infections in Adolescents and Young Adults in the United States: A Retrospective Cohort StudyStatus: Recruiting, Estimated PCD: 2024-03-31
Product
TrumenbaProduct
MenACWY VaccineClinical trial
A Phase II Randomized, Observer-Blind, Placebo-Controlled Study, to Assess the Efficacy of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) in Preventing Gonococcal InfectionStatus: Recruiting, Estimated PCD: 2025-10-15
Clinical trial
Penetration of the Innovative Antibiotic Gepotidacin Into Prostate and Tonsillar Tissue.Status: Completed, Estimated PCD: 2023-05-27
Clinical trial
Superiority of On-demand Pre-exposure Prophylaxis Versus Post-exposure Prophylaxis on Using Doxycycline for Preventing Sexually Transmitted Infections in Men Who Have Sex With MenStatus: Not yet recruiting, Estimated PCD: 2026-10-01
Product
DoxyODPrEPProduct
DoxyPEPClinical trial
Cefixime 800 mg Plus Doxycycline 100 mg b.i.d. for 7 Days Compared to Ceftriaxone 1 g Plus Azithromycin 2 g for Treatment of Urogenital, Rectal and Pharyngeal Gonorrhoea: A Randomised Controlled TrialStatus: Completed, Estimated PCD: 2022-06-30
Product
CefiximeProduct
DoxycyclinProduct
CeftriaxonClinical trial
Clearance of Asymptomatic Pharyngeal Carriage of Neisseria Gonorrhoeae With or Without Ceftriaxone Treatment: Randomized Non-inferiority StudyStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 3 Randomized, Observer-Blind, Placebo-Controlled Study to Assess Efficacy of Meningococcal Group B (rMenB+OMV NZ (Bexsero)) in Preventing Gonococcal Infection Among South African Cis-Gender WomenStatus: Not yet recruiting, Estimated PCD: 2026-05-31
Product
BexseroDrug
VarlilumabClinical trial
Efficacy of a Meningococcal B Vaccine Against Neisseria Gonorrhoeae Infections Among Men Who Have Sex With Men: a Randomised-controlled Clinical TrialStatus: Recruiting, Estimated PCD: 2025-03-01
Product
4CMenBClinical trial
A Multi-center, Randomized, Open-label, Non Inferiority Trial to Evaluate the Efficacy and Safety of a Single, Oral Dose of Zoliflodacin Compared to a Combination of a Single Intramuscular Dose of Ceftriaxone and a Single Oral Dose of Azithromycin in the Treatment of Patients With Uncomplicated GonorrhoeaStatus: Active (not recruiting), Estimated PCD: 2023-08-30
Product
zoliflodacinProduct
ceftriaxoneProduct
azithromycinClinical trial
Division of Microbiology and Infectious Diseases, (DMID) 21-0018: Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria GonorrhoeaeStatus: Recruiting, Estimated PCD: 2028-02-01
Product
CiprofloxacinProduct
Influenza VaccineProduct
Tetanus-Diphtheria VaccineClinical trial
Immunisation for Adolescents Against Serious Communicable DiseasesStatus: Recruiting, Estimated PCD: 2024-12-31
Product
4CMenB VaccineClinical trial
WHO-recommended Periodic Presumptive Treatment Versus Doxycycline Post-Exposure Prophylaxis for STI Control Among Cisgender Men Who Have Sex With Men in KenyaStatus: Not yet recruiting, Estimated PCD: 2028-01-31
Product
Doxycycline